Single-agent pembrolizumab demonstrated modest efficacy in heavily pretreated advanced ovarian cancer in the phase Ib KEYNOTE-028 study in patients with PD-L1-positive tumors and the phase II KEYNOTE-100 study enrolling patients irrespective of PD-L1 status22,23. This evidence concerns the gene CD274 and ovarian carcinoma.